Autoimmunity and brain dysfunction

The Neuroimmunological Basis of Behavior and Mental Disorders

Volumn , Issue , 2009, Pages 341-381

  Hoffman, Steven A ^a   Sakic, Boris ^b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Autism; Autoimmunity; Behavior; Blood brain barrier; Brain pathology; Brain reactive autoantibodies; Complement; Homeostatic metasystem; Immune complexes; Lupus; Mental function; Multiple sclerosis; Neuroactive cytokines; Neuropsychiatric manifestations; Schizoprenia

Indexed keywords

EID: 84870417472     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-84851-8_17     Document Type: Chapter

References (336)

1. Abbott NJ, Mendonca LL, Dolman DE, 2003. The blood-brain barrier in systemic lupus erythematosus. Lupus 12:908-915
2. ACR Ad Hoc Committee, 1999. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 42:599-608
3. Afeltra A, Garzia P, Mitterhofer AP, Vadacca M, Galluzzo S, Del PF, Finamore L, Pascucci S, Gasparini M, Lagana B, Caccavo D, Ferri GM, Amoroso A, Francia A, 2003. Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology 61:108-110
4. Ahlsen G, Rosengren L, Belfrage M, Palm A, Haglid K, Hamberger A, Gillberg C, 1993. Glial fibrillary acidic protein in the cerebrospinal fluid of children with autism and other neuropsychiatric disorders. Biol. Psychiatry 33:734-743
5. Ainiala H, Hietaharju A, Dastidar P, Loukkola J, Lehtimaki T, Peltola J, Korpela M, Heinonen T, Nikkari ST, 2004. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis Rheum. 50:858-865
6. Ainiala H., Loukkola J., Peltola J., Korpela M., Hietaharju A., 2001. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 57:496-500
7. Alcocer-Varela J, Aleman-Hoey D, Alarcon-Segovia D, 1992. Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus 1:111-117
8. Alexander JJ, Bao L, Jacob A, Kraus DM, Holers VM, Quigg RJ, 2003. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis. Biochim. Biophys. Acta 1639: 69-176
9. Alexander JJ, Jacob A, Bao L, Macdonald RL, Quigg RJ, 2005a. Complement-dependent apoptosis and inflammatory gene changes in murine lupus cerebritis. J. Immunol. 175:8312-8319
10. Alexander JJ, Jacob A, Vezina P, Sekine H, Gilkeson GS, Quigg RJ, 2007. Absence of functional alternative complement pathway alleviates lupus cerebritis. Eur. J. Immunol. 37:1691-1701
11. Alexander EL, Murphy ED, Roths JB, Alexander GE, 1983. Congenic autoimmune murine models of central nervous system disease in connective tissue disorders. Ann. Neurol. 14:242-248
12. Alexander JJ, Quigg RJ, 2007. Systemic lupus erythematosus and the brain: what mice are telling us. Neurochem. Int. 50:5-11
13. Alexander JJ, Zwingmann C, Quigg R, 2005b. MRL/lpr mice have alterations in brain metabolism as shown with [(1)H-(13)C] NMR spectroscopy. Neurochem. Int. 47:143-151
14. Alosachie IJ, Terryberry JW, Mevorach D, Chapman Y, Lorber M, Torre D, Youinou P, Peter JB, Shoenfeld Y, 1998. Central nervous system (CNS) involvement in SLE. The diagnostic role of antibodies to neuronal antigens. Clin. Rev. Allergy Immunol. 16:275-284
15. Anderson KK, Ballok DA, Prasad N, Szechtman H, Sakic B, 2006. Impaired response to amphetamine and neuronal degeneration in the nucleus accumbens of autoimmune MRL-lpr mice. Behav. Brain Res. 166:32-38
16. Anisman H, Merali Z, Poulter MO, Hayley S, 2005. Cytokines as a precipitant of depressive illness: animal and human studies. Curr. Pharm. Des. 11:963-972
17. Appenzeller S, Bonilha L, Rio PA, Min LL, Costallat LT, Cendes F, 2007. Longitudinal analysis of gray and white matter loss in patients with systemic lupus erythematosus. Neuroimage. 34:694-701
18. Arolt V, Weitzsch C, Wilke I, Nolte A, Pinnow M, Rothermundt M, Kirchner H, 1997. Production of interferon-gamma in families with multiple occurrence of schizophrenia. Psychiatry Res. 66:145-152
19. Avcin T, Silverman ED, 2007. Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus 16:627-633
20. Ballok DA, 2007. Neuroimmunopathology in a murine model of neuropsychiatric lupus. Brain Res. Rev. 54:67-79
21. Ballok DA, Earls AM, Krasnik C, Hoffman SA, Sakic B, 2004a. Autoimmune-induced damage of the midbrain dopaminergic system in lupus-prone mice. J. Neuroimmunol. 152:83-97
22. Ballok DA, Ma X, Denburg JA, Arsenault L, Sakic B, 2006. Ibuprofen fails to prevent brain pathology in a model of neuropsychiatric lupus. J. Rheumatol. 33:2199-2213
23. Ballok DA, Sakic B. Neurodegeneration in autoimmune mice as revealed by Fluoro Jade B. Society for Neuroscience Abstracts, 93.15. 2002.
24. Ballok DA, Woulfe J, Sur M, Cyr M., Sakic B, 2004b. Hippocampal damage in mouse and human forms of systemic autoimmune disease. Hippocampus 14:649-661
25. Baraczka K, Nekam K, Pozsonyi T, Jakab L, Szongoth M, Sesztak M, 2001. Concentration of soluble adhesion molecules (sVCAM-1, sICAM-1 and sL-selectin) in the cerebrospinal fluid and serum of patients with multiple sclerosis and systemic lupus erythematosus with central nervous involvement. Neuroimmunomodulation. 9:49-54
26. Baraczka K, Nekam K, Pozsonyi T, Szuts I, Ormos G, 2004. Investigation of cytokine (tumor necrosis factor-Alpha, interleukin-6, interleukin-10) concentrations in the cerebrospinal fluid of female patients with multiple sclerosis and systemic lupus erythematosus. Eur. J. Neurol. 11:37-42
27. Bartholomew SA, Hoffman SA, 1993. Effects of peripheral cytokine injections on multiple unit activity in the anterior hypothalamic area of the mouse. Brain Behav. Immun. 7:301-316
28. Beiske AG, Svensson E, Sandanger I, Czujko B, Pedersen ED, Aarseth JH, Myhr KM, 2008. Depression and anxiety amongst multiple sclerosis patients. Eur. J. Neurol. 15:239-245
29. Belmont HM, Hopkins P, Edelson HS, Kaplan HB, Ludewig R, Weissmann G, Abramson S, 1986. Complement activation during systemic lupus erythematosus -C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum. 29:1085-1089
30. Bluestein HG, 1978. Neurocytotoxic antibodies in serum of patients with systemic lupus erythematosus. Proc. Natl. Acad. Sci. U. S. A. 75:3965-3969
31. Bluestein HG, 1979. Heterogeneous neurocytotoxic antibodies in systemic lupus erythematosus. Clin. Exp. Immunol. 35:210.
32. Bluestein HG, Pischel KD, Woods VL, Jr., 1986. Immunopathogenesis of the neuropsychiatric manifestations of systemic lupus erythematosus. Springer Semin. Immunopathol. 9:237-249
33. Bluestein HG, Williams GW, Steinberg AD, 1981. Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am. J. Med. 70:240-246
34. Bluestein HG, Woods VL, 1982. Antineuronal antibodies in systemic lupus erythematosus. Arthritis Rheum. 25:773-778
35. Bluestein HG, Zvaifler NJ, 1976. Brain-reactive lymphocytotoxic antibodies in the serum of patients with systemic lupus erythematosus. J. Clin. Invest. 57:509-516
36. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM, 2001. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinsons disease. Prog. Neurobiol. 65:135-172
37. Borchers AT, Aoki CA, Naguwa SM, Keen CL, Shoenfeld Y, Gershwin ME, 2005. Neuropsychiatric features of systemic lupus erythematosus. Autoimmun. Rev. 4:329-344
38. Borda T, Perez RR, Joensen L, Gomez RM, Sterin-Borda L, 2002. Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: molecular interaction. J. Immunol. 168:3667-3674
39. Bosma GP, Rood MJ, Zwinderman AH, Huizinga TW, van Buchem MA, 2000. Evidence of central nervous system damage in patients with neuropsychiatric systemic lupus erythematosus, demonstrated by magnetization transfer imaging. Arthritis Rheum. 43:48-54
40. Bresnihan B, Hohmeister R, Cutting J, Travers RL, Waldburger M, Black C, Jones T, Hughes GR, 1979. The neuropsychiatric disorder in systemic lupus erythematosus: evidence for both vascular and immune mechanisms. Ann. Rheum. Dis. 38:301-306
41. Brey RL, Cote S, Barohn R, Jackson C, Crawley R, Teale JM, 1995. Model for the neuromuscular complications of systemic lupus erythematosus. Lupus 4:209-212
42. Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, Valdez CR, Escalante A, del R, I, Gronseth G, Rhine CB, Padilla P, McGlasson D, 2002. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58:1214-1220
43. Brey RL, Sakic B, Szechtman H, Denburg JA, 1997. Animal models for nervous system disease in systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 823:97-106
44. Brooks WM, Sabet A, Sibbitt WL, Barker PB, van Zijl PC, Duyn JH, Moonen CT, 1997. Neurochemistry of brain lesions determined by spectroscopic imaging in systemic lupus erythematosus. J. Rheumatol. 24:2323-2329
45. Bruns A, Meyer O, 2006. Neuropsychiatric manifestations of systemic lupus erythematosus. Joint Bone Spine 73:639-645
46. Buka SL, Cannon TD, Torrey EF, Yolken RH, 2008. Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biol. Psychiatry. 63:809-815
47. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH, 2001. Maternal infections and subsequent psychosis among offspring. Arch. Gen. Psychiatry 58:1032-1037
48. Callenbach PM, Jol-Van Der Zijde CM, Geerts AT, Arts WF, Van Donselaar CA, Peters AC, Stroink H, Brouwer OF, Van Tol MJ, 2003. Immunoglobulins in children with epilepsy: the Dutch Study of Epilepsy in Childhood. Clin. Exp. Immunol. 132:144-151
49. Carbotte RM, Denburg SD, Denburg JA, 1986. Prevalence of cognitive impairment in systemic lupus erythematosus. J. Nerv. Ment. Dis. 174:357-364
50. Carr RI, Shucard DW, Hoffman SA, Hoffman AW, Bardana EJ, Harbeck RJ, 1978. In Neurochemical and components of schizophrenia, Goldstein, A.L. and Bergsma, D.(Eds), Birth Defects Orig. Artic. Ser. 14: 209-235
51. Caspi A, Moffitt TE, 2006. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat. Rev. Neurosci. 7:583-590
52. Cazzullo CL, Scarone S, Grassi B, Vismara C, Trabattoni D, Clerici M, 1998. Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Prog. Neuropsychopharmacol. Biol. Psychiatry 22:947-957
53. Chess S, 1977. Follow-up report on autism in congenital rubella. J. Autism Child Schizophr. 7:69-81
54. Chun S, McEvilly R, Foster JA, Sakic B, 2007. Proclivity to self-injurious behavior in MRLlpr mice: implications for autoimmunity-induced damage in the dopaminergic system. Mol. Psychiatry. 1359-4184
55. Comi AM, Zimmerman AW, Frye VH, Law PA, Peeden JN, 1999. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J. Child Neurol. 14:388-394
56. Conejero-Goldberg C, Torrey EF, Yolken RH, 2003. Herpesviruses and Toxoplasma gondii in orbital frontal cortex of psychiatric patients. Schizophr. Res. 60:65-69
57. Connolly AM, Chez MG, Pestronk A, Arnold ST, Mehta S, Deuel RK, 1999. Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J. Pediatr. 134:607-613
58. Correale J, Farez M, Gilmore W, 2008. Vaccines for multiple sclerosis -progress to date. CNS Drugs 22:175-198
59. Crimando J, Cooper K, Hoffman SA, 1997. Inhibition of sodium channel currents by antineuronal autoantibody from autoimmune mice. Ann. N. Y. Acad. Sci. 823:303-307
60. Cronin ME, Biswas RM, Van der Straeton C, Fleisher TA, Klippel JH, 1988. IgG and IgM anticardiolipin antibodies in patients with lupus with anticardiolipin antibody associated clinical syndromes. J. Rheumatol. 15:795-798
61. Daniels WW, Warren RP, Odell JD, Maciulis A, Burger RA, Warren WL, Torres AR, 1995. Increased frequency of the extended or ancestral haplotype B44-SC30-DR4 in autism. Neuropsychobiology 32:120-123
62. Danon YL, Garty BZ, 1986. Autoantibodies to neuroblastoma cell surface antigens in neuropsychiatric lupus. Neuropediatrics 17:23-27
63. Davoust N, Jones J, Stahel PF, Ames RS, Barnum SR, 1999. Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells. Glia 26:201-211
64. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B, 2001. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 7:1189-1193
65. Denburg JA, Carbotte RM, Denburg SD, 1993. Central nervous system lupus. Rheum. Rev. 2:123-132
66. Denburg SD, Carbotte RM, Ginsberg JS, Denburg JA, 1997. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J. Int. Neuropsychol. Soc. 3:377-386
67. Denburg JA, Denburg SD, Carbotte RM, Long AA, Hanly JG, 1988. Nervous system involvement in systemic lupus erythematosus. Isr. J. Med. Sci. 24:754-758
68. Denburg JA, Denburg SD, Carbotte RM, Sakic B, Szechtman H, 1995. Nervous system lupus: pathogenesis and rationale for therapy. Scand. J. Rheumatol. 12:263-273
69. Denenberg VH, Mobraaten LE, Sherman GF, Morrison L, Schrott LM, Waters NS, Rosen GD, Behan PO, Galaburda AM, 1991. Effects of the autoimmune uterine/maternal environment upon cortical ectopias, behavior and autoimmunity. Brain Res. 563:114-122
70. Denenberg VH, Sherman GF, Morrison L, Schrott LM, Waters NS, Rosen GD, Behan PO, Galaburda AM, 1992. Behavior, ectopias and immunity in BD/DB reciprocal crosses. Brain Res. 571:323-329
71. Deykin EY, MacMahon B, 1979. Viral exposure and autism. Am. J. Epidemiol. 109:628-638
72. Diederichsen H, Pyndt IC, 1970. Antibodies against neurons in a patient with systemic lupus erythematosus, cerebral palsy, and epilepsy. Brain 93:407-412
73. Elouaai F, Lule J, Benoist H, Appolinaire-Pilipenko S, Atanassov C, Muller S, Fournie GJ, 1994. Autoimmunity to histones, ubiquitin, and ubiquitinated histone H2A in NZB x NZW and MRL-lpr/lpr mice. Anti-histone antibodies are concentrated in glomerular eluates of lupus mice. Nephrol. Dial. Transplant. 9:362-366
74. Farrell M, Sakic B, Szechtman H, Denburg JA, 1997. Effect of cyclophosphamide on leucocytic infiltration in the brain of MRL/lpr mice. Lupus 6:268-274
75. Feinstein A, 2004. The neuropsychiatry of multiple sclerosis. Can. J. Psychiatry 49:157-163
76. Feinstein A, Feinstein K, Gray T, OConnor P, 1997. Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch. Neurol. 54:1116-1121
77. Feinstein A, OConnor P, Gray T, Feinstein K, 1999. The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis. Mult. Scler. 5:323-326
78. Ferro JM, 1998. Vasculitis of the central nervous system. J. Neurol. 245:766-776
79. Fessel WJ, 1962a. Autoimmunity and mental illness. A preliminary report. Arch. Gen. Psychiatry 6:320-323
80. Fessel WJ, 1962b. Macroglobin elevations in functional mental illness. Nature 193:1005.
81. Fessel WJ, Hirata-Hibi M, 1963. Abnormal leucocytes in schizophrenia. Arch. Gen. Psychiatry 106:601-613
82. Fields RA, Sibbitt WL, Toubbeh H, Bankhurst AD, 1990. Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies. Ann. Rheum. Dis. 49:114-117
83. Fieschi C, Rasura M, Anzini A, Beccia M, 1998. Central nervous system vasculitis. J. Neurol. Sci. 153:159-171
84. Forster MJ, Popper MD, Retz KC, Lal H, 1988a. Age differences in acquisition and retention of one-way avoidance learning in C57BL/6NNia and autoimmune mice. Behav. Neural Biol. 49:139-151
85. Forster MJ, Retz KC, Lal H, 1988b. Learning and memory deficits associated with autoimmunity: significance in aging and Alzheimers disease. Drug Dev. Res. 15:253-273
86. Francis K, Lewis BM, Akatsu H, Monk PN, Cain SA, Scanlon MF, Morgan BP, Ham J, Gasque P, 2003. Complement C3a receptors in the pituitary gland: a novel pathway by which an innate immune molecule releases hormones involved in the control of inflammation. FASEB J. online
87. Ganguli R, Brar JS, Chengappa KN, Yang ZW, Nimgaonkar VL, Rabin BS, 1993. Autoimmunity in schizophrenia: a review of recent findings. Ann. Med. 25:489-496
88. Ganguli R, Brar JS, Rabin BS, 1994. Immune abnormalities in schizophrenia: evidence for the autoimmune hypothesis. Harv. Rev. Psychiatry 2:70-83
89. Gaughran F, 2002. Immunity and schizophrenia: autoimmunity, cytokines, and immune responses. Int. Rev. Neurobiol. 52:275-302
90. Ghaffar O, Feinstein A, 2007. The neuropsychiatry of multiple sclerosis: a review of recent developments. Curr. Opin. Psychiatry 20:278-285
91. Gianani R, Sarvetnick N, 1996. Viruses, cytokines, antigens, and autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 93:2257-2259
92. Gillberg C, 1999. Neurodevelopmental processes and psychological functioning in autism. Dev. Psychopathol. 11:567-587
93. Gitlits VM, Sentry JW, Matthew ML, Smith AI, Toh BH, 2001. Synapsin I identified as a novel brain-specific autoantigen. J. Invest. Med. 49:283
94. Giuliani F, Goodyer CG, Antel JP, Yong VW, 2003. Vulnerability of human neurons to T cellmediated cytotoxicity. J. Immunol. 171:368-379
95. Golombek SJ, Graus G, Elkon KB, 1986. Autoantibodies in the cerebrospinal fluid of patients with systemic lupus erythematosus. Arthritis Rheum. 29:1090-1097
96. Greenwood DL, Gitlits VM, Alderuccio F, Sentry JW, Toh BH, 2002. Autoantibodies in neuropsychiatric lupus. Autoimmunity 35:79-86
97. Gruol DL, Nelson TE, 1997. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol. Neurobiol. 15:307-339
98. Gwag BJ, Koh JY, Demaro JA, Ying HS, Jacquin M, Choi DW, 1997. Slowly triggered excitotoxicity occurs by necrosis in cortical cultures. Neuroscience 77:393-401
99. Handa R, Sahota P, Kumar M, Jagannathan NR, Bal CS, Gulati M, Tripathi BM, Wali JP, 2003. In vivo proton magnetic resonance spectroscopy (MRS) and single photon emission computerized tomography (SPECT) in systemic lupus erythematosus (SLE). Magn Reson. Imaging 21:1033-1037
100. Hanly JG, Fisk JD, Eastwood B, 1994. Brain reactive autoantibodies and cognitive impairment in systemic lupus erythematosus. Lupus 3:193-199
101. Hanly JG, Fisk JD, McCurdy G, Fougere L, Douglas JA, 2005. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. J. Rheumatol. 32:1459-6
102. Hanly JG, Hong C, 1993. Antibodies to brain integral membrane proteins in systemic lupus erythematosus. J. Immunol. Methods 161:107-118
103. Harbeck R, Hoffman AA, Hoffman SA, 1978a. Distribution in isolated brain components of antigens combining with thymocytotoxins in New Zealand mice. Transplantation 25:161-163
104. Harbeck RJ, Hoffman AA, Hoffman SA, Shucard DW, 1979. Cerebrospinal fluid and the choroid plexus during acute immune complex disease. Clin. Immunol. Immunopathol. 13:413-425
105. Harbeck RJ, Hoffman AA, Hoffman SA, Shucard DW, Carr RI, 1978b. A naturally occurring antibody in New Zealand mice cytotoxic to dissociated cerebellar cells. Clin. Exp. Immunol. 31:313-320
106. Harel Y, Barak Y, Achiron A, 2007. Dysregulation of affect in multiple sclerosis: new phenomenological approach. Psychiatry Clin. Neurosci. 61:94-98
107. Harris EN, Hughes GRV, 1985. Cerebral disease in systemic lupus erythematosus. Springer Semin. Immunopathol. 8:251-266
108. Hayley S, Anisman H, 2005. Multiple mechanisms of cytokine action in neurodegenerative and psychiatric states: neurochemical and molecular substrates. Curr. Pharm. Des. 11: 947-962
109. Heath RG, 1969. Schizophrenia: evidence of a pathologic immune mechanism. Proc. Annu. Meet. Am. Psychopathol. Assoc. 58:234-252
110. Heath RG, Krupp IM, 1967. Schizophrenia as an immunologic disorder. I. Demonstration of antibrain globulins by fluorescent antibody techniques. Arch. Gen. Psychiatry 16:1-9
111. Henneberg A, Mayle DM, Kornhuber HH, 1991. Antibodies to brain tissue in sera of patients with chronic progressive multiple sclerosis. J. Neuroimmunol. 34:223-227
112. Hess DC, Taormina M, Thompson J, Sethi KD, Diamond B, Rao R, Feldman DS, 1993. Cognitive and neurologic deficits in the MRL/lpr mouse: a clinicopathologic study. J. Rheumatol. 20:610-617
113. Hickey WF, 1999. Leukocyte traffic in the central nervous system: the participants and their roles. Semin. Immunol. 11:125-137
114. Hickey WF, 2001. Basic principles of immunological surveillance of the normal central nervous system. Glia 36:118-124
115. Hickey WF, Lassmann S, Cross AH, 1997. Lymphocyte entry and the initiation of inflammation in the central nervous system. In: Keane, R. W., Hickey, W. F. (Eds.), Immunology of the Nervous System. Oxford University Press, New York, pp. 200-225
116. Hill PG, McMillan SA, 2006. Anti-tissue transglutaminase antibodies and their role in the investigation of coeliac disease. Ann. Clin. Biochem. 43:105-117
117. Hirano T, Hashimoto H, Shiokawa Y, Iwamori M, Nagai Y, Kasi M, Ochiai Y, Okumura K, 1980. Antiglycolipid autoantibody detected in the sera from systemic lupus erythematosus patients. J. Clin. Invest. 66:1440
118. Hirohata S, Hirose S, Miyamoto T, 1985. Cerebrospinal fluid IgM, IgA, and IgG indexes in systemic lupus erythematosus. Their use as estimates of central nervous system disease activity. Arch. Intern. Med. 145:1843-1846
119. Hirohata S, Miyamoto T, 1990. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum. 33:644-649
120. Hoffman SA, Arbogast DN, Day TT, Shucard DW, Harbeck RJ, 1983. Permeability of the blood cerebrospinal fluid barrier during acute immune complex disease. J. Immunol. 130:1695-1698
121. Hoffman SA, Arbogast DN, Ford PM, Shucard DW, Harbeck RJ, 1987. Brain-reactive autoantibody levels in the sera of ageing autoimmune mice. Clin. Exp. Immunol. 70:74-83
122. Hoffman SA, Ford P, Kubo R, 1988a. Characterization of cell surface antigens on the adrenergic neuroblastoma clone A2(1). Brain Res. 452:358-366
123. Hoffman SA, Harbeck RJ, 1989. CNS lupus and the blood-brain barrier. In: Neuwelt, E A. (Ed.), Implications of the Blood-Brain Barrier and Its Manipulation. Plenum Medical Book Co., New York-London, pp. 469-494
124. Hoffman SA, Hoffman AA, Shucard DW, Harbeck RJ, 1978a. Antibodies to dissociated cerebellar cells in New Zealand mice as demonstrated by immunofluorescence. Brain Res. 142:477-486
125. Hoffman SA, Madsen CS, 1990. Brain specific autoantibodies in murine models of systemic lupus erythematosus. J. Neuroimmunol. 30:229-237
126. Hoffman SA, Narendran A, Shucard DW, Harbeck RJ, 1988b. Autoantibodies, immune complexes, and behavioral disorders: neuropsychiatric involvement in systemic lupus erythematosus. Drug Dev. Res. 15:237-251
127. Hoffman SA, Shucard DW, Brodie HA, Reifenrath C, Harbeck RJ, 1982. Suppression of water intake by immune complex formation in the hypothalamus. Implications for systemic lupus erythematosus. J. Neuroimmunol. 2:167-176
128. Hoffman SA, Shucard DW, Harbeck RJ, 1998. The immune system can affect learning: chronic immune complex disease in a rat model. J. Neuroimmunol. 86:163-170
129. Hoffman SA, Shucard DW, Harbeck RJ, Hoffman AA, 1978b. Chronic immune complex disease: behavioral and immunological correlates. J. Neuropathol. Exp. Neurol. 37:426-436
130. Hogan MJ, Brunet DG, Ford PM, Lillicrap D, 1988. Lupus anticoagulant, antiphospholipid antibodies and migraine. Can. J. Neurol. Sci. 15:420-425
131. Hopkins P, Belmont HM, Buyon J, Philips M, Weissmann G, Abramson SB, 1988. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum. 31:632-641
132. Hornig M, Weissenbock H, Horscroft N, Lipkin WI, 1999. An infection-based model of neurodevelopmental damage. Proc. Natl. Acad. Sci. U. S. A. 96:12102-12107
133. Horwitz MS, Sarvetnick N, 1999. Viruses, host responses, and autoimmunity. Immunol. Rev. 169:241-253
134. How A, Dent PB, Liao SK, Denburg JA, 1985. Antineuronal antibodies in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 28:789-795
135. Huang WS, Chiu PY, Tsai CH, Kao A, Lee CC, 2002. Objective evidence of abnormal regional cerebral blood flow in patients with systemic lupus erythematosus on Tc-99m ECD brain SPECT. Rheumatol. Int. 22:178-181
136. Huerta PT, Kowal C, DeGiorgio LA, Volpe BT, Diamond B, 2006. Immunity and behavior: antibodies alter emotion. Proc. Natl. Acad. Sci. U. S. A. 103:678-683
137. Inzelberg R, Korczyn A, 1989. Lupus anticoagulant and late onset seizures. Acta Neurol. Scand. 79:114-118
138. James WG, Hutchinson P, Bullard DC, Hickey MJ, 2006. Cerebral leucocyte infiltration in lupusprone MRL/MpJ-fas lpr mice-roles of intercellular adhesion molecule-1 and P-selectin. Clin. Exp. Immunol. 144:299-308
139. Jankovic BD, 1985. From immunoneurology to immunopsychiatry: neuromodulating activity of anti-brain antibodies. Int. Rev. Neurobiol. 26:249-314
140. Jara LJ, Irigoyen L, Ortiz, MD, Zazueta B, Bravo G, Espinoza LR, 1998. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin. Rheumatol. 17:110-114
141. Jennekens FG, Kater L, 2002. The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology (Oxford) 41:619-630
142. Johnson RT, Richardson EP, 1968. The neurological manifestations of systemic lupus erythematosus. Medicine 47:337-369
143. Jongen PJ, Doesburg WH, Ibrahim-Stappers JL, Lemmens WA, Hommes OR, Lamers KJ, 2000. Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol. Scand. 101:116-121
144. Jonsen A, Bengtsson AA, Nived O, Ryberg B, Truedsson L, Ronnblom L, Alm GV, Sturfelt G, 2003. The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles. Lupus 12:846-850
145. Kaposi MK, 1872. Neue Beitrage zur Kenntnis des Lupus erythematosus. Arch. Belg. Dermatol. Syphiligr. 4:36-52
146. Kasama T, Odai T, Wakabayashi K, Yajima N, Miwa Y, 2008. Chemokines in systemic lupus erythematosus involving the central nervous system. Front Biosci. 13:2527-2536
147. Katsumata Y, Harigai M, Kawaguchi Y, Fukasawa C, Soejima M, Takagi K, Tanak M, Ichida H, Tochimoto A, Kanno T, Nishimura K, Kamatani N, Hara M, 2007. Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-Alpha, IgG index, and Q-Albumin. J. Rheumatol. 34:2010-2017
148. Katzav A, Solodeev I, Brodsky O, Chapman J, Pick CG, Blank M, Zhang W, Reichlin M, Shoenfeld Y, 2007. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum. 56:938-948
149. Keane RW, Hickey WF, 1997. Immunology of the Nervous System. Oxford University Press, New York
150. Kim RC, Collins GH, Parisi JE, 1982. Rheumatoid nodule formation within the choroid plexus. Report of a second case. Arch. Pathol. Lab. Med. 106:83-84
151. Kirch DG, 1993. Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr. Bull. 19:355-370
152. Kiss E, Shoenfeld Y, 2007. Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus? Clin. Rev. Allergy Immunol. 69:37-46
153. Klein R, Richter C, Berg PA, 1991. Antibodies against central nervous system tissue (anti-CNS) detected by ELISA and western blotting: marker antibodies for neuropsychiatric manifestations in connective tissue diseases. Autoimmunity 10:133-144
154. Komatsu N, Kodama K, Yamanouchi N, Okada S, Noda S, Nawata Y, Takabayashi K, Iwamoto I, Saito Y, Uchida Y, Ito H, Yoshikawa K, Sato T, 1999. Decreased regional cerebral metabolic rate for glucose in systemic lupus erythematosus patients with psychiatric symptoms. Eur. Neurol. 42:41-48
155. Kowal C, DeGiorgio LA, Lee JY, Edgar MA, Huerta PT, Volpe BT, Diamond B, 2006. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc. Natl. Acad. Sci. U. S. A. 103:19854-19859
156. Kowal C, DeGiorgio LA, Nakaoka T, Hetherington H, Huerta PT, Diamond B, Volpe BT, 2004. Cognition and immunity; antibody impairs memory. Immunity. 21:179-188
157. Kozora E, Laudenslager M, Lemieux A, West SG, 2001. Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patients. J. Int. Neuropsychol. Soc. 6:745-754
158. Kraepelin E, 1992. The manifestations of insanity. Hist. Psychiatry 3:509-526
159. Kronfol Z, Remick DG, 2000. Cytokines and the brain: implications for clinical psychiatry. Am. J. Psychiatry 157:683-694
160. Kumar M, Cohen D, Eisdorfer C, 1988. Serum IgG brain reactive antibodies in Alzheimer disease and Down syndrome. Alzheimer Dis. Assoc. Disord. 2:50-55
161. Kumar M, Resnick L, Loewenstein DA, Berger J, Eisdorfer C, 1989. Brain-reactive antibodies and the AIDS dementia complex. J. Acquir. Immune Defic. Syndr. 2:469-471
162. Kurki P, Helve T, Dahl D, Virtanen I, 1986. Neurofilament antibodies in systemic lupus erythematosus. J. Rheumatol. 13:69-73
163. Kwant A, Sakic B, 2004. Behavioral effects of infection with interferon-gamma adenovector. Behav. Brain Res. 151:73-82
164. Lal H, Forster M, Retz KC, Reisberg B, 1988. Immune dysfunctions: new targets of drug discovery for Alzheimers disease and other cognitive disorders. Drug Dev. Res. 15.
165. Lang B, Dale RC, Vincent A, 2003. New autoantibody mediated disorders of the central nervous system. Curr. Opin. Neurol. 16:351-357
166. Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T, Bleiberg J, Rosenstein D, Pao M, Patronas N, Steele S, Manzano M, van d, V, Lipsky PE, Marenco S, Wesley R, Volpe B, Diamond B, Illei GG, 2006. Anti-N-methyl-D-Aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 54:2505-2514
167. Lawrence DA, Bolivar VJ, Hudson CA, Mondal TK, Pabello NG, 2007. Antibody induction of lupus-like neuropsychiatric manifestations. J Neuroimmunol 182:185-194
168. Lawson LJ, Perry VH, Dri P, Gordon S, 1990. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39:151-170
169. Layfield R, Lowe J, Bedford L, 2005. The ubiquitin-proteasome system and neurodegenerative disorders. Essays Biochem. 41:157-171
170. Lehmann-Facius H, 1939. Serologisch-Analytische Versuche mit Liquores und Seren von Schizophrenen. Allg. Z. Psychiatrie 110:232-243
171. Leweke FM, Gerth CW, Koethe D, Klosterkotter J, Ruslanova I, Krivogorsky B, Torrey EF, Yolken RH, 2004. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 254:4-8
172. Liberato B, Levy RA, 2007. Antiphospholipid syndrome and cognition. Clin. Rev. Allergy Immunol. 32:188-191
173. Lin A, Kenis G, Bignotti S, Tura GB, DeJong R, Bosmans E, Pioli R, Altamura C, Scharpe S, Maes M, 1998. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 32:9-15
174. Long AA, Denburg SD, Carbotte RM, Singal DP, Denburg JA, 1990. Serum lymphocytotoxic antibodies and neurocognitive function in systemic lupus erythematosus. Ann. Rheum. Dis. 49:249-253
175. Lopez-Longo FJ, Carol N, Almoguera MI, Olazaran J, onso-Farto JC, Ortega A, Monteagudo I, Gonzalez CM, Carreno L, 2003. Cerebral hypoperfusion detected by SPECT in patients with systemic lupus erythematosus is related to clinical activity and cumulative tissue damage. Lupus 12:813-819
176. Ma X, Foster J, Sakic B, 2006. Distribution and prevalence of leukocyte phenotypes in brains of lupus-prone mice. J. Neuroimmunol. 179:26-36
177. Maag TJ, Hoffman SA, 1993. Anti-brain antibodies in the sera of rheumatoid arthritis patients: relation to disease activity and psychological status. J. Neuroimmunol. 45:37-45
178. Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, Scharpe S, 1997. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 66:1-11
179. Maino K, Gruber R, Riedel M, Seitz N, Schwarz M, Muller N, 2007. T-and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment. Psychiatry Res. 152:173-180
180. Mamula MJ, 1998. Epitope spreading: the role of self peptides and autoantigen processing by B lymphocytes. Immunol. Rev. 164:231-239
181. Margutti P, Delunardo F, Ortona E, 2006. Autoantibodies associated with
182. Maric D, Millward JM, Ballok DA, Szechtman H, Barker JL, Denburg JA, Sakic B, 2001. Neurotoxic properties of cerebrospinal fluid from behaviorally impaired autoimmune mice. Brain Res. 920:183-193
183. McAllister CG, Rapaport MH, Pickar D, Paul SM, 1991. Autoimmunity and schizophrenia. In: Tamminga, C. A., Schultz, S. C. (Eds.), Advances in Neuropsychiatry and Psychopharmacology, vol. 1. Raven Press, Ltd., New York, pp. 111-118
184. McCluskey J, Farris AD, Keech CL, Purcell AW, Rischmueller M, Kinoshita G, Reynolds P, Gordon TP, 1998. Determinant spreading: lessons from animal models and human disease. Immunol. Rev. 164:209-229
185. McIntyre KR, Ayer-LeLievre C, Persson H, 1990. Class II major histocompatibility complex (MHC) gene expression in the mouse brain is elevated in the autoimmune MRL/Mp-lpr/lpr strain. J. Neuroimmunol. 28:39-52
186. McLean BN, Miller D, Thompson EJ, 1995. Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behcets disease involving the nervous system. J. Neurol. Neurosurg. Psychiatry 58:548-554
187. Monastero R, Bettini P, Del Zotto E, Cottini E, Tincani A, Balestrieri G, Cattaneo R, Camarda R, Vignolo LA, Padovani A, 2001. Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations. J. Neurol. Sci.: 33-39
188. Mondal TK, Saha SK, Miller VM, Seegal RF, Lawrence DA, 2008. Autoantibody-mediated neuroinflammation: Pathogenesis of neuropsychiatric systemic lupus erythematosus in the NZM88 murine model. Br. Behav. Immunity 22: 949-959
189. Money J, Bobrow NA, Clarke FC, 1971. Autism and autoimmune disease: a family study. J. Autism Child Schizophr. 1:146-160
190. Monteleone P, Fabrazzo M, Tortorella A, Maj M, 1997. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res. 71:11-17
191. Moore PM, 1997. Autoantibodies to nervous system tissue in human and murine systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 823:289-299
192. Mora F, Segovia G, del Arco A, 2007. Aging, plasticity and environmental enrichment: Structural changes and neurotransmitter dynamics in several areas of the brain Brain Res. Rev. 55: 78-88
193. Mortensen PB, Norgaard-Pedersen B, Waltoft BL, Sorensen TL, Hougaard D, Torrey EF, Yolken RH, 2007. Toxoplasma gondii as a risk factor for early-onset schizophrenia: analysis of filter paper blood samples obtained at birth. Biol. Psychiatry 61:688-693
194. Muller N, 1995. Psychoneuroimmunology: implications for the drug treatment of psychiatric disorders. CNS Drugs 4:125-140
195. Muller N, Ackenheil M, 1995. Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology. Schizophr. Res. 14:223-228
196. Muller N, Empl M, Riedel M, Schwarz M, Ackenheil M, 1997. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 247:308-313
197. Muller N, Schlesinger BC, Hadjamu M, Riedel M, Schwarz M, Ackenheil M, Wank R, Gruber R, 1998. Increased frequency of CD8 positive gamma/delta T-lymphocytes (CD8(+) gamma/ delta(+)) in unmedicated schizophrenic patients: relation to impairment of the blood-brain barrier and HLA-DPA 02011. Schizophr. Res. 32:69-71
198. Muller N, Schwarz M, 2006a. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox. Res. 10:131-148
199. Muller N, Schwarz MJ, 2006b. Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders. Expert. Rev. Neurother. 6:1017-1038
200. Nahmias AJ, Nahmias SB, Danielsson D, 2006. The possible role of transplacentally-Acquired antibodies to infectious agents, with molecular mimicry to nervous system sialic acid epitopes, as causes of neuromental disorders: prevention and vaccine implications. Clin. Dev. Immunol. 13:167-183
201. Narendran A, Hoffman SA, 1988. Identification of autoantibody reactive integral brain membrane antigens -a two dimensional analysis. J. Immunol. Methods 114:227-234
202. Narendran A, Hoffman SA, 1989. Characterization of brain-reactive autoantibodies in murine models of systemic lupus erythematosus. J. Neuroimmunol. 24:113-123
203. Nataf S, Davoust N, Barnum SR, 1998. Kinetics of C5aR expression during experimental allergic encephalomyelitis. J. Neuroimmunol. 91:147-155
204. Naudin J, Mege JL, Azorin JM, Dassa D, 1996. Elevated circulating levels of IL-6 in schizophrenia. Schizophr. Res. 20:269-273
205. Navarrete MG, Brey RL, 2000. Neuropsychiatric Systemic Lupus Erythematosus. Curr. Treat. Options. Neurol. 2:473-485
206. Nikkila HV, Muller K, Ahokas A, Rimon R, Andersson LC, 2001. Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia. Schizophr. Res. 49:99-105
207. Nishimura K, Harigai M, Omori M, Sato E, Hara M, 2008. Blood-brain barrier damage as a risk factor for corticosteroid-induced psychiatric disorders in systemic lupus erythematosus. Psychoneuroendocrinology. 33:395-403
208. Omdal R, Brokstad K, Waterloo K, Koldingsnes W, Jonsson R, Mellgren SI, 2005. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur. J. Neurol. 12:392-398
209. Omdal R, Selseth B, Klow NE, Husby G, Mellgren SI, 1989. Clinical neurological, electrophysiological, and cerebral CT scan findings in systemic lupus erythematosus. Scand. J. Rheumatol. 18:283-289
210. OSullivan FX, Vogelweid CM, Beschwilliford CL, Walker SE, 1995. Differential effects of CD4(+) T cell depletion on inflammatory central nervous system disease, arthritis and sialadenitis in MRL/lpr mice. J. Autoimmun. 8:163-175
211. Owens T, 2003. The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr. Opin. Neurol. 16:259-265
212. Park C, Sakamaki K, Tachibana O, Yamashima T, Yamashita J, Yonehara S, 1998. Expression of Fas antigen in the normal mouse brain. Biochem. Biophys. Res. Commun. 252:623-628
213. Parker LM, Chused TM, Steinberg AD, 1974. Immunofluorescence studies on thymocytotoxic antibody from New Zealand black mice. J. Immunol. 112:285
214. Patten SB, Svenson LW, Metz LM, 2005. Psychotic disorders in MS: population-based evidence of an association. Neurology 65:1123-1125
215. Peress NS, Tompkins DC, 1979. Rat CNS in experimental chronic serum sickness: Integrity of the zonulae occludentes of the choroid plexus epithelium and brain endothelium in experimental chronic serum sickness. Neuropathol. Appl. Neurobiol. 5, 279-288
216. Pollmacher T, Hinze-Selch D, Mullington J, 1996. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol. 16:403-409
217. Quismorio FP, Friou GJ, 1972. Antibodies reactive with neurons in SLE patients with neuropsychiatric manifestations. Int. Arch. Allergy Appl. Immunol. 43:740-748
218. Ramos M, Mandybur TI, 1975. Cerebral vasculitis in rheumatoid arthritis. Arch. Neurol. 32:271-275
219. Rapaport MH, McAllister CG, 1991. Neuroimmunologic factors in schizophrenia. In: Gorman, J. M., Kertzner, R. M. (Eds.), Psychoimmunology Update. American Psychiatric Press, Washington, DC, pp. 31-54
220. Rhodes B, Vyse TJ, 2007. General aspects of the genetics of SLE. Autoimmunity 40: 550-559
221. Rodier PM, 1994. Vulnerable periods and processes during central nervous system development. Environ. Health Perspect. 102 Suppl 2:121-124
222. Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, Kirchner H, 1996. Production of cytokines in acute schizophrenic psychosis. Biol. Psychiatry 40:1294-1297
223. Rudick RA, Eskin TA, 1983. Neuropathological features of a lupus-like disorder in autoimmune mice. Ann. Neurol. 14:325-332
224. Ruiz-Argelles A, Rivadeneyra-Espinoza L, Alarcn-Segovia D, 2003. Antibody penetration into living cells: pathogenic, preventive and immuno-therapeutic implications. Curr. Pharm. Des. 9:1881-1887
225. Sa MJ, 2007. Psychological aspects of multiple sclerosis. Clin. Neurol. Neurosurg. (electronic publication).
226. Sakic B, Denburg JA, Denburg SD, Szechtman H, 1996a. Blunted sensitivity to sucrose in autoimmune MRL-lpr mice: a curve-shift study. Brain Res. Bull. 41:305-311
227. Sakic B, Gurunlian L, Denburg SD, 1998a. Reduced aggressiveness and low testosterone levels in autoimmune MRL-lpr males. Physiol. Behav. 63:305-309
228. Sakic B, Kirkham DL, Ballok DA, Mwanjewe J, Fearon IM, Macri J, Yu G, Sidor MM, Denburg JA, Szechtman H, Lau J, Ball AK, Doering LC, 2005. Proliferating brain cells are a target of neurotoxic CSF in systemic autoimmune disease. J. Neuroimmunol. 169:68-85
229. Sakic B, Kolb B, Whishaw IQ, Gorny G, Szechtman H, Denburg JA, 2000a. Immunosuppression prevents neuronal atrophy in lupus-prone mice: evidence for brain damage induced by autoimmune disease? J. Neuroimmunol. 111:93-101
230. Sakic B, Lacosta S, Denburg J, Szechtman H, 2002. Altered neurotransmission in brains of autoimmune mice: pharmacological and neurochemical evidence. J. Neuroimmunol. 129: 84-96
231. Sakic B, Maric I, Koeberle PD, Millward JM, Szechtman H, Maric D, Denburg JA, 2000b. Increased TUNEL-staining in brains of autoimmune Fas-deficient mice. J. Neuroimmunol. 104:147-154
232. Sakic B, Szechtman H, Braciak TA, Richards CD, Gauldie J, Denburg JA, 1997a. Reduced preference for sucrose in autoimmune mice: a possible role of interleukin-6. Brain Res. Bull. 44:155-165
233. Sakic B, Szechtman H, Denburg JA, 1997b. Neurobehavioral alteration in autoimmune mice. Neurosci. Biobehav. Rev. 21:327-340
234. Sakic B, Szechtman H, Denburg SD, Carbotte RM, Denburg JA, 1993a. Brain-reactive antibodies and behavior of autoimmune MRL-lpr mice. Physiol. Behav. 54:1025-1029
235. Sakic B, Szechtman H, Denburg SD, Carbotte RM, Denburg JA, 1993b. Spatial learning during the course of autoimmune disease in MRL mice. Behav. Brain Res. 54:57-66
236. Sakic B, Szechtman H, Denburg JA, Gorny G, Kolb B, Whishaw IQ, 1998b. Progressive atrophy of pyramidal neuron dendrites in autoimmune MRL-lpr mice. J. Neuroimmunol. 87:162-170
237. Sakic B, Szechtman H, Gauldie J, Denburg JA, 2001. Behavioral effects of infection with IL-6 adenovector. Brain Behav. Immun. 15:25-42
238. Sakic B, Szechtman H, Keffer M, Talangbayan H, Stead R, Denburg JA, 1992. A behavioral profile of autoimmune lupus-prone MRL mice. Brain Behav. Immun. 6:265-285
239. Sakic B, Szechtman H, Stead R, Denburg JA, 1996b. Joint pathology and behavioral performance in autoimmune MRL-lpr mice. Physiol. Behav. 60:901-905
240. Sakic B, Szechtman H, Talangbayan H, Denburg SD, Carbotte RM, Denburg JA, 1994. Disturbed emotionality in autoimmune MRL-lpr mice. Physiol. Behav. 56:609-617
241. Sasajima T, Watanabe H, Sato S, Sato Y, Ohira H, 2006. Anti-triosephosphate isomerase antibodies in cerebrospinal fluid are associated with neuropsychiatric lupus. J. Neuroimmunol. 181:150-156
242. Scarisbrick IA, 2008. The multiple sclerosis degradome: enzymatic cascades in development and progression of central nervous system inflammatory disease. Curr. Top. Microbiol. Immunol. 318:133-175
243. Schiffer RB, Hoffman SA, 1991. Behavioral sequelae of autoimmune disease. In: Ader, R., Felten, D. L., Cohen, N. (Eds.), Psychoneuroimmunology. Academic Press, Inc., San Diego, CA, pp. 1037-1066
244. Schott K, Schaefer JE, Richartz E, Batra A, Eusterschulte B, Klein R, Berg PA, Bartels M, Mann K, Buchkremer G, 2003. Autoantibodies to serotonin in serum of patients with psychiatric disorders. Psychiatry Res. 121:51-57
245. Schrott LM, Crnic LS, 1994. Sensitivity to foot shock in autoimmune NZB x NZW F1 hybrid mice. Physiol. Behav. 56:849-853
246. Schrott LM, Crnic LS, 1996a. Anxiety behavior, exploratory behavior, and activity in NZB x NZW F1 hybrid mice: role of genotype and autoimmune disease progression. Brain Behav. Immun. 10:260-274
247. Schrott LM, Crnic LS, 1996b. The role of performance factors in the active avoidance conditioning deficit in autoimmune mice. Behav. Neurosci. 110:486-491
248. Schrott LM, Crnic LS, 1998. Attenuation of behavioral abnormalities in autoimmune mice by chronic soluble interferon-gamma receptor treatment. Brain Behav. Immun. 12:90-106
249. Schrott LM, Denenberg VH, Sherman GF, Waters NS, Rosen GD, Galaburda AM, 1992. Environmental enrichment, neocortical ectopias, and behavior in the autoimmune NZB mouse. Dev. Brain Res. 67:85-93
250. Schrott LM, Morrison L, Wimer R, Wimer C, Behan PO, Denenberg VH, 1994. Autoimmunity and avoidance learning in NXRF recombinant inbred strains. Brain Behav. Immun. 8:100-110
251. Schrott LM, Waters NS, Boehm GW, Sherman GF, Morrison L, Rosen GD, Galaburda AM, Denenberg VH, 1993. Behavior, cortical ectopias, and autoimmunity in BXSB-Yaa and BXSB-Yaa+ mice. Brain Behav. Immun. 7:205-223
252. Schupf N, Williams CA, 1985. Effect of immune complex forming reactants on catecholaminemodulated behaviors in the rat hypothalamus. J. Neuroimmunol. 9:13-27
253. Schupf N, Williams CA, 1987. Psychopharmacological activity of immune complexes in rat brain is complement dependent. J. Neuroimmunol. 13:293-303
254. Schupf N, Williams CA, Hugli TE, Cox J, 1983. Psychopharmacological activity of anaphylatoxin C3a in rat hypothalamus. J. Neuroimmunol. 5:305-316
255. Schwartz M, Silver H, 2000. Lymphocytes, autoantibodies and psychosis-coincidence versus etiological factor: an update. Isr. J. Psychiatry Relat. Sci. 37:32-36
256. Scolding NJ, Joseph FG, 2002. The neuropathology and pathogenesis of systemic lupus erythematosus. Neuropathol. Appl. Neurobiol. 28:173-189
257. Sherman GF, Galaburda AM, Behan PO, Rosen GD, 1987. Neuroanatomical anomalies in autoimmune mice. Acta Neuropathol. (Berl.) 74:239-242
258. Sherman GF, Morrison L, Rosen GD, Behan PO, Galaburda AM, 1990a. Brain abnormalities in immune defective mice. Brain Res. 532:25-33
259. Sherman GF, Stone JS, Press DM, Rosen GD, Galaburda AM, 1990b. Abnormal architecture and connections disclosed by neurofilament staining in the cerebral cortex of autoimmune mice. Brain Res. 529:202-207
260. Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T, 1992. Interferon-Alpha in lupus psychosis. Arthritis Rheum. 35:417-422
261. Shirai T, Mellors RC, 1971. Natural thymocytotoxic autoantibody and reactive antigen in New Zealand Black and other mice. Proc. Natl. Acad. Sci. U. S. A. 68:1412-1415
262. Shirai T, Mellors RC, 1972. Natural cytotoxic autoantibody against thymocytes in NZB mice. Clin. Exp. Immunol. 12:133-152
263. Shoenfeld Y, Aron-Maor A, 2000. Vaccination and autoimmunity-vaccinosis: a dangerous liaison? J. Autoimmun. 14:1-10
264. Shucard JL, Parrish J, Shucard DW, McCabe DC, Benedict RH, Ambrus J, Jr., 2004. Working memory and processing speed deficits in systemic lupus erythematosus as measured by the paced auditory serial addition test. J. Int. Neuropsychol. Soc. 10:35-45
265. Sibbitt WL, Haseler LJ, Griffey RH, Hart BL, Sibbitt RR, Matwiyoff NA, 1994. Analysis of cerebral structural changes in systemic lupus erythematosus by proton MR spectroscopy. AJNR Am. J. Neuroradiol. 15:923-928
266. Sibbitt WL, Sibbitt RR, 1993. Magnetic resonance spectroscopy and positron emission tomography scanning in neuropsychiatric systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 19:851-868
267. Sidor MM, Sakic B, Malinowski PM, Ballok DA, Oleschuk CJ, Macri J, 2005. Elevated immunoglobulin levels in the cerebrospinal fluid from lupus-prone mice. J. Neuroimmunol. 165:104-113
268. Silva SC, Correia C, Fesel C, Barreto M, Coutinho AM, Marques C, Miguel TS, Ataide A, Bento C, Borges L, Oliveira G, Vicente AM, 2004. Autoantibody repertoires to brain tissue in autism nuclear families. J. Neuroimmunol. 152:176-182
269. Singer GG, Carrera AC, Marshakrothstein A, Martineza C, Abbas AK, 1994. Apoptosis, fas and systemic autoimmunity: The MRL-Ipr/Ipr model. Curr. Opin. Immunol. 6: 913-920
270. Singh VK, 1996. Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism. J. Neuroimmunol. 66:143-145
271. Singh VK, Jensen RL, 2003. Elevated levels of measles antibodies in children with autism. Pediatr. Neurol. 28:292-294
272. Singh VK, Lin SX, Newell E, Nelson C, 2002. Abnormal measles-mumps- rubella antibodies and CNS autoimmunity in children with autism. J. Biomed. Sci. 9: 359-364
273. Singh VK, Rivas WH, 2004. Prevalence of serum antibodies to caudate nucleus in autistic children. Neurosci. Lett. 355:53-56
274. Singh VK, Warren R, Averett R, Ghaziuddin M, 1997. Circulating autoantibodies to neuronal and glial filament proteins in autism. Pediatr. Neurol. 17:88-90
275. Sirota P, Schild K, Elizur A, Djaldetti M, Fishman P, 1995. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 19:75-83
276. Sofat N, Malik O, Higgens C, 2006. Neurological involvement in patients with rheumatic disease. QJM 99:69-79
277. Sokol DK, McIntyre JA, Wagenknecht DR, Dropcho EJ, Patel H, Salanova V, da Costa G, 2004. Antiphospholipid and glutamic acid decarboxylase antibodies in patients with focal epilepsy. Neurology 62:517-518
278. Solomon GF, Allansmith M, McCellan B, Amkraut A, 1969. Immunoglobulins in psychiatric patients. Arch. Gen. Psychiatry 20:272-277
279. Solomon GF, Moos RH, Fessel WJ, Morgan EE, 1966. Globulins and behavior in schizophrenia. Int. J. Neuropsychiatry 2:20-26
280. Steens SC, Admiraal-Behloul F, Bosma GP, Steup-Beekman GM, Olofsen H, Le CS, Huizinga TW, van Buchem MA, 2004. Selective gray matter damage in neuropsychiatric lupus. Arthritis Rheum. 50:2877-2881
281. Steiner JW, Gelbloom AJ, 1959. Intracranial manifestations in two cases of systemic rheumatoid disease. Arthritis Rheum. 2:537-545
282. Stubbs EG, 1976. Autistic children exhibit undetectable hemagglutination-inhibition antibody titers despite previous rubella vaccination. J. Autism Child Schizophr. 6:269-274
283. Szechtman H, Sakic B, Denburg JA, 1997. Behaviour of MRL mice: an animal model of disturbed behaviour in systemic autoimmune disease. Lupus 6:223-229
284. Tanaka S, Matsunaga H, Kimura M, Tatsumi K, Hidaka Y, Takano T, Uema T, Takeda M, Amino N, 2003. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J. Neuroimmunol. 141:155-164
285. Temesvari P, Denburg J, Denburg S, Carbotte R, Bensen W, Singal D, 1983. Serum lymphocytotoxic antibodies in neuropsychiatric lupus: A serial study. Clin. Immunol. Immunopathol. 28:243.
286. Theofilopoulos AN, 1992. Murine models of lupus. In: Lahita, R. G. (Ed.), Systemic Lupus Erythematosus. Churchill Livingstone, New York, pp. 121-194
287. Toh BH, Mackay IR, 1981. Autoantibody to a novel neuronal antigen in systemic lupus erythematosus and in normal human sera. Clin. Exp. Immunol. 44:555-559
288. Tomer Y, Davies TF, 1995. Infections and autoimmune endocrine disease. Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 9:47-70
289. Tomita M, Holman BJ, Santoro TJ, 2001a. Aberrant cytokine gene expression in the hippocampus in murine systemic lupus erythematosus. Neurosci. Lett. 302:129-132
290. Tomita M, Holman BJ, Williams LS, Pang KC, Santoro TJ, 2001b. Cerebellar dysfunction is associated with overexpression of proinflammatory cytokine genes in lupus. J. Neurosci. Res. 64:26-33
291. Tomita M, Khan RL, Blehm BH, Santoro TJ, 2004. The potential pathogenetic link between peripheral immune activation and the central innate immune response in neuropsychiatric systemic lupus erythematosus. Med. Hypotheses 62:325-335
292. Torrey EF, Bartko JJ, Lun ZR, Yolken RH, 2007. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-Analysis. Schizophr. Bull. 33:729-736
293. Torrey EF, Leweke MF, Schwarz MJ, Mueller N, Bachmann S, Schroeder J, Dickerson F, Yolken RH, 2006. Cytomegalovirus and schizophrenia. CNS Drugs 20:879-885
294. Torrey EF, Yolken RH, 2001. The schizophrenia-rheumatoid arthritis connection: infectious, immune, or both? Brain Behav. Immun. 15:401-410
295. Toubi E, Khamashta MA, Panarra A, Hughes GRV, 1995. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am. J. Med. 99:397-401
296. Toubi E, Shoenfeld Y, 2007. Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun. Rev. 6:119-125
297. Trottier G, Srivastava L, Walker CD, 1999. Etiology of infantile autism: a review of recent advances in genetic and neurobiological research. J. Psychiatry Neurosci. 24:103-115
298. Trysberg E, Nylen K, Rosengren LE, Tarkowski A, 2003. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum. 48:2881-2887
299. Trysberg E, Tarkowski A, 2004. Cerebral inflammation and degeneration in systemic lupus erythematosus. Curr. Opin. Rheumatol. 16:527-533
300. Tsai CY, Wu TH, Tsai ST, Chen KH, Thajeb P, Lin WM, Yu HS, Yu CL, 1994. Cerebrospinal fluid interleukin-6, prostaglandin E2 and autoantibodies in patients with neuropsychiatric systemic lupus erythematosus and central nervous system infections. Scand. J. Rheumatol. 23:57-63
301. Uhlig H, Dernick R, 1989. Monoclonal autoantibodies derived from multiple sclerosis patients and control persons and their reactivities with antigens of the central nervous system. Autoimmunity 5:87-99
302. van Dam AP, Wekking EM, Callewaert JAC, Schipperijn AJM, Oomen HAPC, Dejong J, Swaak AJG, Smeenk RJT, Feltkamp TEW, 1994. Psychiatric symptoms before systemic lupus erythematosus is diagnosed. Rheumatol. Int. 14:57-62
303. van Gent T, Heijnen CJ, Treffers PD, 1997. Autism and the immune system. J. Child Psychol. Psychiatry 38:337-349
304. Vianello M, Tavolato B, Giometto B, 2002. Glutamic acid decarboxylase autoantibodies and neurological disorders. Neurol. Sci. 23:145-151
305. Vincent A, Dalton P, Clover L, Palace J, Lang B, 2003. Antibodies to neuronal targets in neurological and psychiatric diseases. Ann. N. Y. Acad. Sci. 992:48-55
306. Vogelweid CM, Johnson GC, Besch-Williford CL, Basler J, Walker SE, 1991. Inflammatory central nervous system disease in lupus-prone MRL/lpr mice: comparative histologic and immunohistochemical findings. J. Neuroimmunol. 35:89-99
307. Vogelweid CM, Wright DC, Johnson JC, Hewett JE, Walker SE, 1994. Evaluation of memory, learning ability, and clinical neurologic function in pathogen-free mice with systemic lupus erythematosus. Arthritis Rheum. 37:889-897
308. Volkow ND, Warner N, McIntyre R, Valentine A, Kulkarni M, Mullani N, Gould L, 1988. Cerebral involvement in systemic lupus erythematosus. Am. J. Physiol. Imaging 3:91-98
309. Warren RP, Foster A, Margaretten NC, 1987. Reduced natural killer cell activity in autism. J. Am. Acad. Child Adolesc. Psychiatry 26:333-335
310. Warren RP, Margaretten NC, Pace NC, Foster A, 1986. Immune abnormalities in patients with autism. J. Autism Dev. Disord. 16:189-197
311. Warren RP, Odell JD, Warren WL, Burger RA, Maciulis A, Daniels WW, Torres AR, 1996. Strong association of the third hypervariable region of HLA-DR beta 1 with autism. J. Neuroimmunol. 67:97-102
312. Warren RP, Singh VK, 1996. Elevated serotonin levels in autism: association with the major histocompatibility complex. Neuropsychobiology 34:72-75
313. Warren RP, Yonk J, Burger RW, Odell D, Warren WL, 1995. DR-positive T cells in autism: association with decreased plasma levels of the complement C4B protein. Neuropsychobiology 31:53-57
314. Warren RP, Yonk LJ, Burger RA, Cole P, Odell JD, Warren WL, White E, Singh VK, 1990. Deficiency of suppressor-inducer (CD4 + CD45RA+) T cells in autism. Immunol. Invest. 19:245-251
315. Waterloo K, Omdal R, Jacobsen EA, Klow NE, Husby G, Torbergsen T, Mellgren SI, 1999. Cerebral computed tomography and electroencephalography compared with neuropsychological findings in systemic lupus erythematosus. J. Neurol. 246:706-711
316. Waterloo K, Omdal R, Sjoholm H, Koldingsnes W, Jacobsen EA, Sundsfjord JA, Husby G, Mellgren SI, 2001. Neuropsychological dysfunction in systemic lupus erythematosus is not associated with changes in cerebral blood flow. J. Neurol. 248:595-602
317. Wekking EM, 1993. Psychiatric symptoms in systemic lupus erythematosus -an update. Psychosom. Med. 55:219-228
318. Wekking EM, Nossent JC, van Dam AP, Swaak AJ, 1991. Cognitive and emotional disturbances in systemic lupus erythematosus. Psychother. Psychosom. 55:126-131
319. Wilke I, Arolt V, Rothermundt M, Weitzsch C, Hornberg M, Kirchner H, 1996. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci. 246:279-284
320. Williams GW, Bluestein HG, Steinberg AD, 1981. Brain-reactive lymphocytotoxic antibody in the cerebrospinal fluid of patients with systemic lupus erythematosus: correlation with central nervous system involvement. Clin. Immunol. Immunopathol. 18:126-132
321. Williams CA, Schupf N, 1977. Antigen-Antibody reactions in rat brain sites induce transient changes in drinking behavior. Science 196:328-331
322. Williams CA, Schupf N, Hugli TE, 1985. Anaphylatoxin C5a modulation of an alpha-Adrenergic receptor system in the rat hypothalamus. J. Neuroimmunol. 9:29-40
323. Williams CA, Schupf N, Reilly CL, Wagner J, 1988. Complement peptides and neuronal dysfunction in the central nervous system -specificity of receptor sites for anapylatoxin C3a activity in the rat hypothalamus. Drug Dev. Res. 15:175-187
324. Wilson HA, Winfield JB, Lahita RG, Koffler D, 1979. Autoantibody to a novel neuronal antigen in systemic lupus erythematosus and in normal human sera. Arthritis Rheum. 22:458-462
325. Winfield JB, Brunner CM, Koffler D, 1978. Serologic studies in patients with systemic lupus erythematosus and central nervous system dysfunction. Arthritis Rheum. 21:289-294
326. Winfield JB, Shaw M, Silverman LM, Eisenberg RA, Wilson HA, III, Koffler D, 1983. Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction. Am. J. Med. 74:837-844
327. Yolken R, 2004. Viruses and schizophrenia: a focus on herpes simplex virus. Herpes 11 Suppl 2:83A-88A.
328. Yonk LJ, Warren RP, Burger RA, Cole P, Odell JD, Warren WL, White E, 1990 CD4+ helper T cell depression in autism. Immunol. Lett. 25:341-345
329. Yoshida A, Shishido F, Kato K, Watanabe H, Seino O, 2007. Evaluation of cerebral perfusion in patients with neuropsychiatric systemic lupus erythematosus using 123I-IMP SPECT. Ann. Nucl. Med. 21:151-158
330. Yoshio T, Hirata D, Onda K, Nara H, Minota S, 2005. Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. J. Rheumatol. 32:34-39
331. Zameer A, Hoffman SA, 2001. Immunoglobulin binding to brain in autoimmune mice. J. Neuroimmunol. 120:10-18
332. Zameer A, Hoffman SA, 2003. Increased ICAM-1 and VCAM-1 expression in the brains of autoimmune mice. J. Neuroimmunol. 142:67-74
333. Zameer A, Hoffman SA, 2004. B and T cells in the brains of autoimmune mice. J. Neuroimmunol. 146:133-139
334. Zandman-Goddard G, Chapman J, Shoenfeld Y, 2007. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin. Arthritis Rheum. 36:297-315
335. Zimmerman AW, Frye VH, Potter NT, 1993. Immunological aspects of autism. Int. Pediatr. 8:161-166
336. Ziv Y, Schwartz M, 2008. Immune-based regulation of adult neurogenesis: implications for learning and memory. Brain Behav. Immun. 22:167-176.